Related content

Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy

By Kalina Jennifer L.   Neilson David S.   Comber Alexandra P.   Rauw Jennifer M.   Alexander Abraham S.   Vergidis Joanna   Lum Julian J.  

Cancers, Vol. 9, Iss. 2, 2017-01 ,pp. : 13-13

MDPI

Access to resources Recommend Favorite

Trends in the use of androgen deprivation in prostate cancer

By Salminen Eeva   Wickström Jan-Erik   Vahlberg Tero   Duchesne Gillian  

Acta Oncologica, Vol. 43, Iss. 4, 2004-06 ,pp. : 382-387

Informa Healthcare

Access to resources Recommend Favorite

Prognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT)

By Cho D.   Di Blasio C.J.   Rhee A.C.   Kattan M.W.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 4, 2003-07 ,pp. : 282-291

Elsevier

Access to resources Recommend Favorite

Living alone, obesity and smoking: Important factors for quality of life after radiotherapy and androgen deprivation therapy for prostate cancer

By Dieperink Karin B.   Hansen Steinbjørn   Wagner Lis   Johansen Christoffer   Andersen Klaus K.   Hansen Olfred  

Acta Oncologica, Vol. 51, Iss. 6, 2012-07 ,pp. : 722-729

Informa Healthcare

Access to resources Recommend Favorite

Short-term androgen deprivation and PSA doubling time: their association and relationship to disease progression after radiation therapy for prostate cancer

By Hanlon A.L.   Horwitz E.M.   Hanks G.E.   Pollack A.  

International Journal of Radiation Oncology*Biology*Physics, Vol. 58, Iss. 1, 2004-01 ,pp. : 43-52

Elsevier

Access to resources Recommend Favorite